Chengdu Antejin Biotechnology Co., Ltd.

评价2月龄（最小满6 周龄）和3月龄婴幼儿完成基础免疫3剂和加强免疫1剂13价肺炎球菌结合疫苗接种后的免疫持久性。

1、与对照苗比较，评价试验疫苗在2月龄（最小满6周龄）和3月龄婴幼儿中按照相应免疫程序接种后的免疫原性； 2、评价试验疫苗在2月龄（最小满6周龄）和3月龄人群中接种后的安全性。

This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months. The main objectives of the study include: 1. To evaluate the immunogenicity of the trial vaccine in infants aged 2 months (at least 6 weeks) following the corresponding immunization schedule compared to the control vaccine; 2. To evaluate the immunogenicity of the trial vaccine in infants aged 3 months following the corresponding immunization schedule compared to the 2-month group; 3. To evaluate the safety of the trial vaccine in infants aged 2 months (at least 6 weeks) and 3 months following the corresponding immunization schedule.